DNA Methylation Market Growth Opportunities and Forecast till 2030
The Global DNA Methylation Market Size accounted for USD 1,349 Million in 2021 and is anticipated to reach USD 4,067 Million by 2030 with a CAGR of 13.2% from 2022 to 2030.
DNA methylation is an epigenetic method that occurs when a methyl (CH3) group is added to DNA, often modifying gene function and affecting gene expression. The quest to discover the Human Epigenome has recently begun, necessitating the modernization of prior DNA methylation profiling techniques. We describe the major advances in methodologies used to investigate the elusive epigenome over the last three decades (or methylome). The first techniques relied on chromatography to separate methylated and unmethylated cytosines.
Parameter |
DNA Methylation Market |
DNA Methylation Market Size in 2021 |
US$ 1,349 Million |
DNA Methylation Market Forecast By 2030 |
US$ 4,067 Million |
DNA Methylation Market CAGR During 2022 – 2030 |
13.2% |
DNA Methylation Market Analysis Period |
2018 - 2030 |
DNA Methylation Market Base Year |
2021 |
DNA Methylation Market Forecast Data |
2022 - 2030 |
Segments Covered |
By Product, By Application, By Technology, By End-User, and By Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled |
Abcam plc, Active Motif, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Diagenode, Illumina, Inc., Merck Millipore, New England Biolabs, PerkinElmer, Inc., QIAGEN, Thermo Fisher Scientific, and Zymo Research. |
Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Market Dynamics
The rising use of DNA methylation technology in oncology research, as well as the increasing prevalence of various cancers in patients worldwide, is expected to drive global DNA methylation market revenue growth. Other factors anticipated to produce to market revenue increase during the forecast period include increasing use of DNA methylation as epigenetic biomarkers and rising use of DNA methylation in DNA sequencing analyses. Government funding is also a major growth factor for the DNA methylation market, as increased government funding is expected to help research institutes and key players develop and market novel assays useful for the diagnosis of various tumours. As funding increases, the cancer profiling market will become more liquid, and companies will develop new testing methods to identify the underlying mutations that may be the cause of the disease. As a result, all of these factors are expected to contribute to market growth during the forecast period.
Scientists have made numerous discoveries about DNA methylation and its importance in a variety of cellular processes such as carcinogenesis, chromosome stability, embryonic development, gene suppression, genomic imprinting, and X-chromosome inactivation in recent decades. Scientists have linked abnormal DNA methylation to a variety of negative outcomes, including human diseases.
Market Insights
The five categories of the global DNA methylation market are product, application, technology, end-user, and region. The segmentation based on the product includes cell enzymes, kits, instruments and consumables, reagents, and bioinformatics tools. Metabolic diseases, oncology, immunology, and others are among the application segments included in the segmentation. Based on technology, the market is split into DNA methylation, histone methylation, and others. Furthermore, Academic and Research Institutes, pharmaceutical and biotechnology companies, and contract research organizations (CROs) are considered under the end-user segment.
Global DNA Methylation Market Geographical Competition
The global DNA methylation market is divided into five geographical areas: North America, Europe, Latin America, Asia-Pacific, the Middle East, and Africa. In the upcoming years, North America will command a sizeable market share in the global DNA methylation market. Through funding, the regional government supports ongoing epigenetic research initiatives, which contributes to the expansion of the North American regional market. Contrarily, Asia Pacific is anticipated to expand at the fastest rate during the forecast period due to factors such as increasing disposable income, a high patient population with unmet medical needs, increased awareness of early diagnosis, and the availability of efficient treatment options in developing nations, particularly China and India, which fuel the expansion of the global DNA methylation market.
Global DNA Methylation Market Segment Analysis
DNA Methylation Market By Product
o Kits
o Bisulfite Conversion Kits
o ChIP-sequencing Kits
o RNA sequencing Kits
o Whole Genomic Amplification Kits
o 5-hmC and 5-mC Analysis Kits
o Others
· Enzymes
o DNA-modifying Enzymes
o Protein-modifying Enzymes
o RNA-modifying Enzymes
· Instruments and Consumables
o Next-generation Sequencers
o qPCR
o Mass Spectrometers
o Sonicators
o Others
· Reagents
o Antibodies
o Buffers
o Histones
o Magnetic Beads
o Primers
o Others
· Bioinformatics Tools
DNA Methylation Market By Application
· Metabolic Diseases
· Oncology
· Immunology
· Others
DNA Methylation Market By Technology
· DNA Methylation
· Histone Modifications
· Others
DNA Methylation Market By End-User
· Academic and Research Institutes
· Pharmaceutical and Biotechnology Companies
· Contract Research Organizations (CROs)
DNA Methylation Market Leading Companies
This section of the study honors the market's top vendors Abcam plc, Active Motif, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Diagenode, Illumina, Inc., Merck Millipore, New England Biolabs, PerkinElmer, Inc., QIAGEN, Thermo Fisher Scientific, and Zymo Research.
DNA Methylation Market Regions
North America
· U.S.
· Canada
Europe
· U.K.
· Germany
· France
· Spain
· Rest of Europe
Latin America
· Brazil
· Mexico
· Rest of Latin America
Asia-Pacific
· China
· Japan
· India
· Australia
· South Korea
· Rest of Asia-Pacific
Middle East & Africa
· GCC
· South Africa
· Rest of Middle East & Africa